Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder

Major Depressive Disorder Clinical Trial

Official title: Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder: An Open-Label Trial

Status Terminated

Clinical Trial Summary

This proposed study sets out to examine the antidepressant effects of tocilizumab among patients with treatment-refractory major depression.

Clinical Trial Description

As the understanding of the complex relationship between pro-inflammatory cytokines (specifically interleukin-6 [IL-6]) and depression symptoms becomes clearer, clinical trials to evaluate effective and novel treatments are needed. As there have been no published tocilizumab trials among patients with major depression, this pilot study will adopt a single-arm, open-label design. Due to the notion that inflammatory cytokines may play a role in a sub-type of depression, this study will recruit patients with treatment refractory major depressive disorder, for whom established depression treatments have not been effective. In conducting this trial, the investigators seek to examine the potential role of tocilizumab as an augmentation agent, with the hypothesis that it could reduce depression symptomatology in patients with major depression who have not experienced symptom reduction through more traditional antidepressant therapies. ;

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

• NCT number: NCT02660528
• Study type: Interventional
• Source: Brigham and Women's Hospital
• Status: Terminated
• Phase: Phase 2
• Start date: April 2016
• Completion date: June 2020